Search results for "DAQ"
showing 3 items of 13 documents
Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
2016
ABSTRACT Objective: To evaluate the cost-effectiveness of bedaquiline plus background drug regimens (BR) for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in Italy. Methods: A Markov model was adapted to the Italian setting to estimate the incremental cost-effectiveness ratio (ICER) of bedaquiline plus BR (BBR) versus BR in the treatment of MDR-TB and XDR-TB over 10 years, from both the National Health Service (NHS) and societal perspective. Cost-effectiveness was evaluated in terms of life-years gained (LYG). Clinical data were sourced from trials; resource consumption for compared treatments was modelled according to advice from an expert c…
Necesidad de tratamiento ortodóncico e impacto psicosocial de la estética dental en los adolescentes de la Comunidad Valenciana (2010)
2014
La Conferencia de Alma Ata sobre Atención Primaria de Salud en 1978 declaró que ''la salud es un estado de completo bienestar físico, mental y el bienestar social y no una mera ausencia de enfermedades o dolencias''. La maloclusión se ha asociado con problemas psicosociales derivados de una estética dentofacial deficiente, alteraciones funcionales en los casos más extremos (puede verse alterada el habla, la masticación y la articulación temporo-mandibular, entre otras) y una mayor susceptibilidad de desarrollar enfermedad periodontal, caries o sufrir traumatismos dentales; así, debe ser considerada como un problema de salud. La maloclusión no es una enfermedad en el sentido estricto por lo …
In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Inje…
2021
This study evaluated in vitro and in vivo drug release of bedaquiline from in situ forming gels (ISGs) containing 200 mg eq./g bedaquiline fumarate salt prepared with four different grades of poly(d,l-lactide) (PDLLA) or poly(d,l-lactide-co-glycolide) (PLGA) with a lactide/glycolide ratio of 50/50 or 75/25 and acid (A) or ester (E) end-capping in N-methyl-2-pyrrolidone at a polymer/solvent ratio of 20/80% (w/w). Mean in vitro drug release in 0.05 M phosphate buffer pH 7.4 with 1% (w/v) sodium lauryl sulphate was 37.3, 47.1, 53.3, and 62.3% within 28 days for ISGs containing PLGA5050A, PDLLA, PLGA7525A, and PLGA7525E, respectively. The data suggested that drug release was primarily controlle…